Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.

NCT05631626 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

21

Enrollment

INDUSTRY

Sponsor class

Conditions

ADHD
ADHD - Combined Type
Attention Deficit Hyperactivity Disorder Combined
Attention Deficit Hyperactivity Disorder

Interventions

DRUG: CTx-1301 - Dexmethylphenidate 25mg
DRUG: CTx-1301 - Dexmethylphenidate 37.5mg
DRUG: CTx-1301 - Dexmethylphenidate 50mg
DRUG: Placebo

Sponsor

Cingulate Therapeutics

Collaborators

[object Object]